These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22963483)

  • 1. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes.
    Connelly KA; Zhang Y; Advani A; Advani SL; Thai K; Yuen DA; Gilbert RE
    Cardiovasc Ther; 2013 Oct; 31(5):259-67. PubMed ID: 22963483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1α.
    Connelly KA; Advani A; Zhang Y; Advani SL; Kabir G; Abadeh A; Desjardins JF; Mitchell M; Thai K; Gilbert RE
    J Diabetes; 2016 Jan; 8(1):63-75. PubMed ID: 25565455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.
    Glorie L; Behets GJ; Baerts L; De Meester I; D'Haese PC; Verhulst A
    Am J Physiol Endocrinol Metab; 2014 Sep; 307(5):E447-55. PubMed ID: 25053403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats.
    Liu YS; Huang ZW; Wang L; Liu XX; Wang YM; Zhang Y; Zhang M
    J Pharmacol Sci; 2015 Mar; 127(3):260-74. PubMed ID: 25837922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
    Inthachai T; Lekawanvijit S; Kumfu S; Apaijai N; Pongkan W; Chattipakorn SC; Chattipakorn N
    Exp Physiol; 2015 Jun; 100(6):667-79. PubMed ID: 25823534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction.
    Zhang Y; Elsik M; Edgley AJ; Cox AJ; Kompa AR; Wang B; Tan CY; Khong FL; Stapleton DI; Zammit S; Williams SJ; Gilbert RE; Krum H; Kelly DJ
    Int J Cardiol; 2013 Sep; 168(2):1174-85. PubMed ID: 23219315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
    Yamaguchi T; Watanabe A; Tanaka M; Shiota M; Osada-Oka M; Sano S; Yoshiyama M; Miura K; Kitajima S; Matsunaga S; Tomita S; Iwao H; Izumi Y
    J Pharmacol Sci; 2019 Feb; 139(2):112-119. PubMed ID: 30638989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
    See F; Thomas W; Way K; Tzanidis A; Kompa A; Lewis D; Itescu S; Krum H
    J Am Coll Cardiol; 2004 Oct; 44(8):1679-89. PubMed ID: 15489104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4.
    Hamdani N; Hervent AS; Vandekerckhove L; Matheeussen V; Demolder M; Baerts L; De Meester I; Linke WA; Paulus WJ; De Keulenaer GW
    Cardiovasc Res; 2014 Dec; 104(3):423-31. PubMed ID: 25341892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
    Sauvé M; Ban K; Momen MA; Zhou YQ; Henkelman RM; Husain M; Drucker DJ
    Diabetes; 2010 Apr; 59(4):1063-73. PubMed ID: 20097729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II type 1 receptor blocker attenuates exacerbated left ventricular remodeling and failure in diabetes-associated myocardial infarction.
    Matsusaka H; Kinugawa S; Ide T; Matsushima S; Shiomi T; Kubota T; Sunagawa K; Tsutsui H
    J Cardiovasc Pharmacol; 2006 Sep; 48(3):95-102. PubMed ID: 17031262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction.
    Kompa AR; See F; Lewis DA; Adrahtas A; Cantwell DM; Wang BH; Krum H
    J Pharmacol Exp Ther; 2008 Jun; 325(3):741-50. PubMed ID: 18334667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction.
    Apaijai N; Inthachai T; Lekawanvijit S; Chattipakorn SC; Chattipakorn N
    J Endocrinol; 2016 Jun; 229(3):245-58. PubMed ID: 27044778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-myocardial infarct p27 fusion protein intravenous delivery averts adverse remodelling and improves heart function and survival in rodents.
    Konecny F; Zou J; Husain M; von Harsdorf R
    Cardiovasc Res; 2012 Jun; 94(3):492-500. PubMed ID: 22492676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of perindopril on left ventricular remodeling and myocardial osteopontin expression in rats with myocardial infarction].
    Zhang YL; Zhou SX; Wang MH; Wang JF
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1584-8. PubMed ID: 17121705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DPP-4 inhibition has beneficial effects on the heart after myocardial infarction.
    Kubota A; Takano H; Wang H; Hasegawa H; Tadokoro H; Hirose M; Kobara Y; Yamada-Inagawa T; Komuro I; Kobayashi Y
    J Mol Cell Cardiol; 2016 Feb; 91():72-80. PubMed ID: 26739213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S100B: role in cardiac remodeling and function following myocardial infarction in diabetes.
    Mohammadzadeh F; Desjardins JF; Tsoporis JN; Proteau G; Leong-Poi H; Parker TG
    Life Sci; 2013 Mar; 92(11):639-47. PubMed ID: 23000886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction.
    Huang BS; White RA; Ahmad M; Tan J; Jeng AY; Leenen FH
    Cardiovasc Res; 2009 Feb; 81(3):574-81. PubMed ID: 18689429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
    Sanganalmath SK; Barta J; Takeda N; Kumamoto H; Dhalla NS
    Can J Physiol Pharmacol; 2008 Apr; 86(4):180-9. PubMed ID: 18418427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of Trimetazidine upon ventricular remodeling and GLUT4 in diabetic rats after myocardial infarction].
    Zhang RY; Yu P; Wang F; Shen JX; Wang YM
    Zhonghua Yi Xue Za Zhi; 2009 May; 89(18):1240-5. PubMed ID: 19595176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.